Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596867 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Propanolol in Breast Cancer
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02596867: Clinical Trial Phase 2 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
NCT02596867 is a Phase 2 study that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02596867, a Phase 2 study, was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial is a Phase II study using the "window-of-opportunity" design in which the treatment-free window between breast cancer diagnosis and surgical tumor resection is used to study the biological effects of the beta blocker propranolol .
Primary Outcome
to evaluate effect of beta adrenergic blockades on breast cancer at by Ki67 percentage change- we are looking at at least 10% mean change in the tumor proliferative index following propranolol treatment
Interventions
- DRUG propanolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 2 |
Why NCT02596867 stopped before completion
NCT02596867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which propanolol is the first listed.
NCT02596867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02596867 about?
NCT02596867 is a clinical study titled "Neoadjuvant Propanolol in Breast Cancer". This trial is a Phase II study using the "window-of-opportunity" design in which the treatment-free window between breast cancer diagnosis and surgical tumor resection is used to study the biological effects of the beta blocker propranolol .
What is the current status of trial NCT02596867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-09-01. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT02596867?
The interventions under investigation include: propanolol (DRUG).
Who is sponsoring clinical trial NCT02596867?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02596867's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI